Results 171 to 180 of about 50,045 (313)

Very low dislocation rate and good clinical outcome after Bereiter trochleoplasty and additional procedures following the Copenhagen patella–femoral instability algorithm: One‐ and two‐years outcomes from a consecutive cohort of 368 cases

open access: yesKnee Surgery, Sports Traumatology, Arthroscopy, Volume 34, Issue 1, Page 52-63, January 2026.
Abstract Purpose Patello–femoral instability (PFI) is often caused by predisposing factors, with trochlea dysplasia (TD) as the most prominent. Untreated patellar instability leads to impaired function and an increased risk of patellofemoral osteoarthritis.
Christian Dippmann   +4 more
wiley   +1 more source

Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study. [PDF]

open access: yesRes Pract Thromb Haemost
Astermark J   +6 more
europepmc   +1 more source

Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts

open access: yesPediatric Blood &Cancer, Volume 73, Issue 1, January 2026.
ABSTRACT Background Hemophilia A (HA) is a rare bleeding disorder caused by coagulation factor VIII (FVIII) deficiency. Prophylactic FVIII replacement therapy is essential for preventing bleeds, but it carries a risk of inhibitor development, especially in previously untreated and minimally treated patients (PUPs and MTPs, respectively).
Sarina Levy‐Mendelovich   +11 more
wiley   +1 more source

Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B. [PDF]

open access: yesN Engl J Med
Reiss UM   +27 more
europepmc   +1 more source

Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system [PDF]

open access: hybrid, 2016
Frank DeRosa   +10 more
openalex   +1 more source

Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting [PDF]

open access: hybrid, 2020
Cihan Ay   +4 more
openalex   +1 more source

Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components

open access: yesSmall Methods, Volume 10, Issue 2, 22 January 2026.
The review presents a comprehensive overview of each component of lipid nanoparticles(LNPs)and their effects on editing efficiency. It specifically highlights strategies for achieving non‐liver delivery, aiming for broader applications in gene editing. Furthermore, this review summarizes the applications of LNPs in gene editing and offers insights for ...
Fan Wu   +6 more
wiley   +1 more source

Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials. [PDF]

open access: yesNat Med
Xue F   +18 more
europepmc   +1 more source

A Multicenter Clinical Study of Monoclonal Antibody-Purified Coagulation Factor IX Concentrate (GA-1013) in Treatment of Hemophilia B

open access: bronze, 1991
Hiromu Fukui   +25 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy